TY - JOUR
T1 - Hypomethylating Agents-associated Infections—Systematic Review and Meta-analysis of Randomized Controlled Trials
AU - Shargian-Alon, Liat
AU - Gurion, Ronit
AU - Raanani, Pia
AU - Yahav, Dafna
AU - Gafter-Gvili, Anat
N1 - Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/9
Y1 - 2018/9
N2 - Data regarding the effects of hypomethylating agents on the risk of infections are lacking. Therefore, we conducted a systematic review and meta-analysis of all randomized controlled trials comparing hypomethylating agent-containing regimens with any other regimen for patients with myeloid neoplasms. Treatment with hypomethylating agents was associated with an increase in the grade 3/4 infection rate compared with the comparator. Background: The reported data regarding the effects of hypomethylating agents (HMAs) on the risk of infections seem to be poorly documented and heterogeneous. We conducted a systematic review and meta-analysis of all randomized controlled trials comparing HMA-containing regimens with any other regimen administered to patients with myeloid neoplasms. Materials and Methods: A comprehensive search was conducted until February 2018. Two reviewers appraised the quality of the trials and the extracted data. The primary outcome was grade 3/4 infections. The secondary outcomes included febrile neutropenia, fever of unknown origin, grade 3/4 neutropenia, infection-related mortality, and all-cause mortality. The relative risks (RRs) and 95% confidence intervals (CIs) were estimated and pooled. A fixed-effect model was used to pool the data unless significant heterogeneity was present, in which case a random-effects model was used. Results: We identified 9 trials reported from 2002 to 2016 and randomizing 2184 patients. HMAs were associated with an increase in grade 3/4 infections compared with the comparator (RR, 1.30; 95% CI, 1.02-1.66). This was true for the subgroup of patients aged >60 years (RR, 1.19; 95% CI, 1.01-1.39). In addition, HMAs resulted in an increase in the rate of fever of unknown origin and neutropenia (RR, 1.48; 95% CI, 1.15-1.92; RR, 1.48; 95% CI, 1.22-1.78, respectively). Although no difference was found in the incidence of fatal infections (RR, 1.44; 95% CI, 0.72 to 2.89), treatment with HMA reduced the incidence of all-cause mortality (RR, 0.74; 95% CI, 0.66-0.88). Conclusion: Treatment with HMAs was associated with an increase in the grade 3/4 infection rate.
AB - Data regarding the effects of hypomethylating agents on the risk of infections are lacking. Therefore, we conducted a systematic review and meta-analysis of all randomized controlled trials comparing hypomethylating agent-containing regimens with any other regimen for patients with myeloid neoplasms. Treatment with hypomethylating agents was associated with an increase in the grade 3/4 infection rate compared with the comparator. Background: The reported data regarding the effects of hypomethylating agents (HMAs) on the risk of infections seem to be poorly documented and heterogeneous. We conducted a systematic review and meta-analysis of all randomized controlled trials comparing HMA-containing regimens with any other regimen administered to patients with myeloid neoplasms. Materials and Methods: A comprehensive search was conducted until February 2018. Two reviewers appraised the quality of the trials and the extracted data. The primary outcome was grade 3/4 infections. The secondary outcomes included febrile neutropenia, fever of unknown origin, grade 3/4 neutropenia, infection-related mortality, and all-cause mortality. The relative risks (RRs) and 95% confidence intervals (CIs) were estimated and pooled. A fixed-effect model was used to pool the data unless significant heterogeneity was present, in which case a random-effects model was used. Results: We identified 9 trials reported from 2002 to 2016 and randomizing 2184 patients. HMAs were associated with an increase in grade 3/4 infections compared with the comparator (RR, 1.30; 95% CI, 1.02-1.66). This was true for the subgroup of patients aged >60 years (RR, 1.19; 95% CI, 1.01-1.39). In addition, HMAs resulted in an increase in the rate of fever of unknown origin and neutropenia (RR, 1.48; 95% CI, 1.15-1.92; RR, 1.48; 95% CI, 1.22-1.78, respectively). Although no difference was found in the incidence of fatal infections (RR, 1.44; 95% CI, 0.72 to 2.89), treatment with HMA reduced the incidence of all-cause mortality (RR, 0.74; 95% CI, 0.66-0.88). Conclusion: Treatment with HMAs was associated with an increase in the grade 3/4 infection rate.
KW - Azacitidine
KW - Decitabine
KW - HMAs
KW - Infection
KW - Neutropenia
UR - http://www.scopus.com/inward/record.url?scp=85048524347&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2018.05.017
DO - 10.1016/j.clml.2018.05.017
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 29921527
AN - SCOPUS:85048524347
SN - 2152-2650
VL - 18
SP - 603-610.e1
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 9
ER -